geoffrey modest medical blogs

as a reference to the Lp(a) studies in the pipeline, one of which involved direct PCSK9 effects: enclisiran (which is also spelled inclisiran in the NJM study...), which the FDA unexpectedly (by me) approved without documentation of clinical benefit: https://gmodestmedblogs.blogspot.com/2025/11/oral-pcsk9-improves-all-bad-lipids.html  - -- as a summary of what I have found of several of these Lp(a) inhibitors:     -- muvalapin (oral small-molecule): 63-65% reduction in Lp(a), with benefit within 4 weeks: https://jamanetwork.com/journals/jama/fullarticle/2808864       -- pelacarsen (antisense oligonucleotide that targets the Lp(a) gene): up to 80% reduction in Lp(a):   https://www.sciencedirect.com/science/article/pii/S1933287425003228     -- evinacumab (anti-ANGPTL3 mAb): 16.5% reduction in Lp(a): https://www.sciencedirect.com/science/article/pii/S1933287425003228     -- lomitapide (microsomal triglyceride transf...

  As we all know increasingly well, artificial intelligence is gaining prominence in all aspects of our lives, and certainly so in the field of medicine. there are clear benefits from this, but also increasingly clear downsides. does AI provide accurate information? -- there are persistent concerns about the quality and accuracy of the information -- in a very early AI model, i personally found that AI had very well referenced journal articles to back up their recommendations about medical questions. the problem was that the citations were often to very specific articles that actually did not exist. the prevailing explanation was that it was important for people to get an answer, whether right or wrong, in order to accept AI's value -- one of the founders of Open AI was interviewed on NPR recently. He became disenchanted with AI and the direction it was going, and he took it on himself to assess the accuracy of AI responses continually over time     -- his findings have c...